Clinical Trial

Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia

Study acronym: CEFTOREA
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated September 25, 2024 (before its estimated February 2025 completion). Its status may not reflect the trial's current state.
Summary
The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-06-26; most recent amendment 2024-09-23.
Status change: Not Yet Recruiting → Recruiting 2019-03-29
Trial Details
NCT Number NCT03581370
Lead Sponsor University Hospital, Toulouse
Conditions Ventilator-associated Pneumonia
Enrollment 80 participants
Start Date 2018-09-20
Primary Completion 2025-02 (estimated)
Study Completion 2025-02 (estimated)
Updated on ClinicalTrials.gov 2024-09-25